When Sheriann Baker was diagnosed with terminal brain cancer in 2017 doctors told her she could have just two years to live. Three years on she’s tumour free and she claims it’s all down to Rick Simpson oil; a high-THC cannabis oil.
“I’m not going to die of cancer,” says Sheriann Baker, speaking to Cannabis Health from her home in Toronto, Canada.
“I honestly believe I will lead a full life.”
She’s pretty confident, for a woman who three years ago had a tumour the size of a golf ball on her brain and was given – worst case scenario – two years to live.
Sheriann had suffered from migraines since the age of five and as an adult could experience up to 20 severe episodes a month, but she was always prescribed painkillers and the cause was never explored further.
It was June 2017 when Sheriann, then 46, was staying with a friend in British Columbia that she realised something was seriously wrong.
“That morning I had experienced this overwhelming smell of burnt tar,” she remembers.
“We went out to a parade and I started to feel really strange. My left foot was fine, but as I stepped down on my right foot, it was like stepping into a pool of water.
“By the time we got to the car I was completely paralysed. I couldn’t get my brain to tell the rest of my body to move.
“My girlfriend drove me to the hospital and got me admitted – and that’s the last thing I remember.”
Sheriann had suffered an eight minute grand mal seizure, which doctors initially thought was caused by a stroke. Three months later in August, following an appointment with her neurologist, an MRI scan showed the tumour.
“At 46-years-old I was told that I had five to 10 years to live at most,” says Sheriann.
“If I didn’t do chemotherapy and radiation, I would most likely die within two years.”
She continues: “That’s where my research started.
“I’ve always been very against chemotherapy and radiation, I know a lot of people who have died from cancer and told me how brutal it is, if I’ve only got a few years left, that’s not a way I want to live.”
A year earlier, Sheriann had lost a good friend, who had begun using Rick Simpson oil (RSO) – cannabis product known for containing higher levels of THC – after he was diagnosed with lung cancer.
Rick Simpson claims to have cured his metastatic skin cancer in 2003 by using the high grade hemp oil, which is said to include a particular type of cannabis called Cannabis indica, which produces a sedative effect that helps the body heal. The oil is not a branded product – there are various versions available and Simpson’s own website even explains how to make his namesake oil.
Sheriann’s friend sadly passed away from a splint rupturing his lung, but the autopsy is said to have revealed that he was cancer-free.
“That’s when I just knew, I was 150 percent convinced that I needed to try cannabis oil,” she says.
A few months later, Sheriann underwent a six-hour brain surgery. Doctors warned her they wouldn’t be able to remove the whole tumour and three percent was left behind.
She recovered quickly, leaving hospital after 26 hours and two months later was almost completely healed.
“I told my doctors I was using cannabis oil, it’s really important that patients tell their doctors because it can lower your blood pressure,” she says.
“Thankfully they were fantastic and couldn’t believe how great I looked afterwards. I woke up feeling so grateful to be alive and so positive because I had that confidence in the oil.”
A few months later a follow up MRI scan showed that the remaining three percent of the tumour had gone, she says.
“I still have brain cancer, but the cannabis is keeping the tumour from growing back.”
She adds: “It’s now three years later and I feel amazing, my blood work, cholesterol, everything is above average.”
Sheriann continues to take one to two tablets a day of RSO (of 70-75 percent THC and above) mixed with frankincense drops and coconut oil and also eats a completely ‘clean’ diet, cutting out red meat, dairy, carbs, fats and sugar and living mostly on homemade juices.
After she decided to share her journey on social media shortly after she was diagnosed, she is now a full-time influencer and spends her days engaging with and educating her 20,000 followers.
“I have talked to thousands of people around the world who have fought and won against cancer using cannabis oil – every day I get probably five to 10 people reaching out to me,” she says
“We’re saving our own lives and other people need to know about it.”
While she dedicates a lot of her time to raising awareness about the potential benefits of cannabis oil, she is careful not to force it on others
“I’ve lost friends to cancer who weren’t using the oil and it breaks my heart, but you can’t push it on people, you have to let them do their own research and make that decision,” she adds
“People are just afraid, they have been told all their life that it’s a bad drug, they don’t realise the medical benefits.”
RSO was not included in the legalisation of cannabis products in Canada in 2018, due to its high concentrate of THC.
Following a 1975 study which showed THC and other cannabinoids to have a reducing effect on the growth of cancer cells in mice, a number of other studies have been carried out to examine their effectiveness, including a few early-stage trials on humans.
However, much larger and longer term trials are needed to provide conclusive evidence.
“I show all my scans and medical reports online and have even gone to Health Canada, but haven’t had a response from them,” says Sheriann.
“I do get angry about it and I’m not scared to say things online, I’ll take that chance. If they want to throw me in jail with terminal brain cancer, all power to them.”
Several high profile cannabis growers and producers have reached out to Sheriann to donate oil and she was even invited to speak at a national neurologists conference in Toronto earlier this year (which was unfortunately cancelled due to covid).
She laughs: “I couldn’t even believe it when I got invited, I’m just a Canadian girl who started living this lifestyle and am winning because of it.”
Ironically, Sheriann says the three years since she was diagnosed with cancer have been the best of her life.
“When you get the diagnosis, your whole life changes, but I wouldn’t change it for anything,” she says.
“I’ve had people unfollow me because they are in a place where they can’t see the light, but people with cancer can still be happy and have a life.
“I really believe that seeing the positive in everything is a huge thing.”
Sheriann adds: I remember the first time I went into hospital, I was sitting with all these other cancer patients, and they’d all given up.
“I’m not giving up, that’s not me. You have to be as positive as you possibly can until the end.”
CBGA may be ‘more potent’ than CBD against seizures in Dravet syndrome
Dr Lyndsey Anderson said there is more to explore when it comes to creating more treatment options for Dravet syndrome.
Scientists say they have found the ‘Mother of all cannabinoids’ which may help to reduce seizures in Dravet syndrome.
A new study on mice from the University of Sydney found that three acidic cannabinoids found in cannabis reduced seizures in Dravet syndrome, an intractable form of childhood epilepsy.
The three cannabinoids are cannabigerolic acid (CBGA), cannabidivarinic acid (CBDVA), cannabigerovarinic acid (CBGVA). All three but CBGA in particular “may contribute to the effects of cannabis-based products in childhood epilepsy” noted the researchers and were found to potentially have ‘anticonvulsant properties.”
The study marks the first time that three acidic cannabinoids were found to potentially help reduce seizures for Dravet syndrome.
Speaking with Cannabis Health News, the lead author of the study, Dr Lyndsey Anderson, said: “We found that CBGA exhibited both anticonvulsant and pro-convulsant effects. CBGA was more potent than CBD against febrile seizures in a mouse model of Dravet syndrome. We also found that a combination of CBGA and clobazam was more effective than either treatment alone. Additionally, we found that CBGA was anticonvulsant in the maximal electroshock acute seizure model, a model for generalized tonic-clonic seizures.”
She added: “CBGA did, however, present some proconvulsant effects. The frequency of spontaneous seizures in the mouse model of Dravet syndrome was increased with a high dose of CBGA. Also, CBGA was proconvulsant in the 6-Hz acute seizure model, a model of focal, psychomotor seizures.”
Although CBGA shows promise, Dr Anderson also stressed that it needs more research before it can replace CBD. She cautioned that Dravet syndrome patients may still need to proceed with caution.
“Artisanal cannabis-based products are believed to reduce seizures in Dravet syndrome patients,” she said. “As these oils contain rare cannabinoids like CBGA, it is possible CBGA then contributes to the anticonvulsant effects of these artisanal cannabis oils. However, there were proconvulsant effects observed with CBGA, suggesting that Dravet syndrome patients may need to proceed with caution. The proconvulsant liability of CBGA would need to be addressed before it replaced CBD as an anticonvulsant.”
What is CBGA?
Sometimes referred to as ‘the mother of all cannabinoids,’ CBGA is the precursor molecule to many different cannabinioids including CBD and THC. It is thought to help some diseases such as colon cancer, metabolic disease and cardiovascular disease. It is a non-intoxicating cannabinoid much like CBD.
Dr Anderson explains that more research is needed to explain how the three cannabinoids work together.
“We don’t know how they work together yet,” she said. “We found that CBGA, CBDVA and CBGVA were all individually anticonvulsant against thermally induced seizures in the mouse model of Dravet syndrome. We did not investigate whether a combination of these three cannabinoids would result in a greater anticonvulsant effect than either cannabinoid alone. Future work will definitely explore this possibility.”
CBGA future research
This isn’t the end of the research into CBGA for Dravet Syndrome. Dr Anderson said there is more to explore when it comes to creating more treatment options for Dravet syndrome.
She said: “Next on the horizon for this research is to explore whether the anticonvulsant properties of CBDVA and CBGVA translate to other seizure types including spontaneous seizures in the mouse model of Dravet syndrome. Additionally, we have extensively interrogated the anticonvulsant potential of individual cannabinoids and identified ten with anticonvulsant properties.”
“We are now interested in investigating what happens when we combine these anticonvulsant properties. It remains an open possibility that greater anticonvulsant effects are achieved when the cannabinoids are administered in combination.”
New York regulators vote to allow home grow for medical cannabis patients
The new regulations would allow medical cannabis patients and carers in the state a safe, cost-effective way to access their medication
The proposed regulations would allow medical cannabis patients and carers in New York to grow up to six plants, indoors or outdoors, for therapeutic use.
New York cannabis regulators voted unanimously for the proposed regulations which would not only allow qualified patients to grow their own plants.
According to a slide from the Cannabis Control Board presentation, patients would be allowed six plants each but carers with more than one patient, can “cultivate 1 additional cannabis plant for each subsequent patient.”
The new regulations would impose a duty on patients to ensure no one under the age of 21 can access the plants or any products cultivated from them.
Landlords would also have the option to prohibit their tenants from growing cannabis on their property if they chose. The products must not be processed using anything other than alcohol.
The regulations will now have a 60-day public commentary period before review.
Tremaine Wright, chair of the Cannabis Control Board (CCB) said: “We are proud to present those proposed regulations. The home cultivation of medical cannabis will provide certified patients with a cost-effective means of obtaining cannabis through personal cultivation while creating a set of standards governing the conduct and activities relating to the personal cultivation of cannabis.”
In a press release, the CCB also gave an update on the expungement of cannabis convictions. “Approximately 203,000 cannabis-related charges are presently being suppressed from criminal background searches and are in process of being expunged, adding to the approximately 198,000 records that were expunged as part of the first round of cannabis expungement following legislation enacted in 2019.”
New York recreational market
Earlier this year, New York. It would become the 16th US state to legalise recreational cannabis creating thousands of jobs and tax revenue. The bill was signed into law by Governor Andrew Cuomo in March.
The law would allow for possession of up to three ounces of marijuana for personal use. It would allow licensed dispensaries to sell cannabis products to those over 21.
Neighbouring states who have already legalised marijuana, including New Jersey and Massachusetts, meant that New York citizens were leaving to access cannabis losing tax revenue in the process.
It is expected that home grow for recreational users will follow the proposed regulations for medical cannabis patients but only after the new market is established.
CiiTECH announces new CPD-accredited training course
It aims to support and encourage UK pharmacists, physicians and nurses.
Cannabis healthcare company CiiTECH has been awarded CPD accreditation for its academy course, which aims to support and encourage UK pharmacists, physicians and nurses.
CiiTECH’s Cannabis Science and Therapeutics course has had tremendous success after launching the course earlier this year.
The new and innovative course offers an interactive digital platform with a 12 chapter syllabus comprising of medical cannabis, CBD knowledge and information, specifically catered for healthcare professionals in the UK.
Industry experts in the UK could potentially face serious challenges if the trainers in question who are both recommending, and dispensing information are not up to the required standards in the field.
People currently working in the industry, such as pharmacy professionals will feel more secure and confident after taking the course. With such an array of knowledge from the experts, they are better able to recommend, treat and understand benefits and causes of their patients.
Besides all the learning and comprehensive information, simple FAQ questions by patients can be simply downloaded to have at hand as an ongoing reference.
The CBD industry is an extremely fast growing market, people are becoming more and more aware of benefits and common usage. It’s said that by 2025 the market in the UK only will be worth over £3 billion.
This means that clinics and pharmacies must be sourcing trustworthy information to their customers.
This course is aimed at filling an education gap in the market, by covering several points in intricate detail, from plant history to dosing, and patient care. A lot of occupations in the UK require an on going learning process each year, with positive results overtime, leading to a greater service in the industry.
“Through years of experience serving UK customers with our portfolio of CBD brands it was abundantly clear that the level of misinformation was enormous and confusing for everyone involved,” says Clifton Flack, CEO and founder of CiiTECH.
“Formal education is always important but with little to no existence in the UK we could not see a better way to help lead the industry than to establish our own online academy and give healthcare professionals the opportunity to not only learn about cannabis therapeutics but to earn further education points at the same time.”
Flack adds: “With the rise in UK cannabis prescriptions and CiiTECH’s long awaited move into the THC medical cannabis arena, now is the time to increase professional education and it is exactly why we have embarked on this education journey. CiiTECH is fast becoming the UK’s one stop shop for all your cannabis needs; research, education, consumer brands.”
CiiTECH collaborated with Medical Cannabis Mentor to produce the course and prepare it for CPD certification.
Joe Dolce, founder and CEO of Medical Cannabis Mentor, comments: “The course synthesises the most up-to-date scientific research and clinical guidelines in an engaging format to help professionals make informed treatment decisions.”
Introducing our new B2B title
- CBGA may be ‘more potent’ than CBD against seizures in Dravet syndrome
- New York regulators vote to allow home grow for medical cannabis patients
- Grow Pharma to launch own-brand cannabis flower
- Cannabis linked to lower obesity rates in hepatitis B patients – study
- ADHD patients say cannabis helps ease symptoms
- New UK trials to study medical cannabis and chronic pain
News11 months ago
Community extends support to cannabis icon Rick Simpson
News1 year ago
NHS lines up cannabis medicine manufacturing
Case Studies2 years ago
CBD oil and fibromyalgia – a case study
Insight1 year ago
I’ve gone from a wheelchair to walking thanks to cannabis
News10 months ago
UK grants second licence to grow high-THC medical cannabis
Feature1 year ago
Medical cannabis could help long-term effects of COVID-19, says David Nutt
News11 months ago
Living with chronic fatigue – my CBD story
Industry9 months ago
“Game changer” for the sector: First cannabis company expected to list on LSE next month